• Stimulating the Power of Diversity.
  • Stimulating the Power of Diversity.
  • Stimulating the Power of Diversity.
  • Stimulating the Power of Diversity.

Diversity and Function matters

The MAB Discovery platform relies on the broad natural immune response and antibody maturation of wild type rabbits combined with B cell cloning. By doing so, we generate a plethora of therapeutic monoclonal antibody candidates which cover various target epitopes, show diverse functional properties and have high affinities requiring no further optimization. It is this diversity generation that we are striving for. And this is enabled by our proprietary, high-performance technology platform.

Our Partners

BIONTECH
Boehringer Ingelheim
Genmab
iOmx
SANOFI
Synthon
  • About Us.

We are a Team of extremely talented and energetic People, who are passionate about pursuing each new Project.

MAB Discovery GmbH based in Munich, was founded in 2010 and started operations in 2011 with experienced pharma scientists with a proven track record in drug development. MAB Discovery complies with the highest industrial standards of big pharma, but operates with the flexibility, speed and innovative spirit of a young biotech. The company’s outstanding technology platform offers its collaboration partners access to a large variety of fully functional drug candidates, and a unique route to CMC-compliant humanized mAb’s in 10-12 months.

Management

Dr. Stephan Fischer, CEO

Dr. Fischer spent 26 years in R&D at Boehringer-Mannheim/Roche Pharma Research where he focused on the discovery and development of biological based therapeutics.Stephan was a member of the team that developed erythropoietin (NeoRecormon®) and was the scientific and global project leader of the team that developed the thrombolytic reteplase (Retavase®, Rapilysin®) from discovery to launch. Stephan was a member of the global regulatory strategy committee for Biologics and the global task force for biosimilars. As Senior Vice President, Stephan led the Biologics research organization and developed the global strategy for Roche Biologicals with a focus on innovation and new technologies. Stephan received his PhD in Microbiology and conducted his post-doc at the European Molecular Biology Labs.

Dr. Hans-Willi Krell, VP Operations

For over 26 years at Boehringer Mannheim / Roche, Dr. Krell was responsible for the development of high through put assays and screening of new diagnostic and biotechnological enzymes, natural compounds and low molecular weight compounds. More recently, Hans has focused on the discovery and characterization of novel therapeutic antibodies, employing innovative biochemical and cell based screens. In addition, Hans has been actively involved in global project management. Hans (co-) authored more than 40 patent applications and 60 publications. Hans holds a PhD from Freiburg University in biochemistry.

  • Philosophy

Rabbit immune system is an unrivaled system for generating antibody diversity

Rabbit antibodies are known for their excellent affinities and specificities; even generating antibodies to unique epitopes. The explanation for these attributes and the broad diversity of antibodies are the mechanisms employed by the rabbit immune system [read more].

Large diversity requires high throughput technologies

In order to yield the most diverse repertoire of target specific rabbit antibodies, and to allow for a fast identification of the monoclonal antibody with the best functional profile, as many of the IgG expressing B-cell clones as possible are selected and screened in an automated process. 15,000 to 60,000 B-cell clones are isolated and cultured individually per campaign. The secreted monoclonal antibodies can be functionally tested in high throughput assays.

Sequence diversity

After sequencing thousands of target-specific antibody genes, it is remarkable that we have never isolated the same sequence from different rabbits immunized with the same immunogen. This supports the assumption that gene conversion produces individual rabbits with a unique gene repertoire for antibodies. Also, the sequence redundancy rate in one individual animal is very low. This is the result of the empirically optimized immunization and sampling protocol. We can guarantee novel sequences from each campaign, a solid basis for IP [read more].

Fc isotype diversity

Function, efficacy and safety profile of therapeutic antibodies can be highly dependent on the antibody isotypes and Fc modifications. Therefore, we introduced special features to allow for flexibility in targeted modification of the antibody’s Fc part [read more].

Outcome: Unique antibodies with diverse functionality

Altogether, the above-mentioned factors and procedures result in sets of functional antibodies with unique and diverse functional profiles [read more].

  • Technology & Innovations

Stimulating the Power of Diversity

Secrets of Success of the MAB Discovery Platform:

  • Wild-type rabbits create very potent antibodies with pM affinities already in an early phase of the immune response.
  • Affinity maturation is not required to isolate potent molecules.
  • Activity screens are possible in B-cell supernatants, including screening for Fc function and cell binding assays.
  • Each rabbit is unique and will create novel antibodies.
  • Very low sequence redundancy within one animal (< 10%).
  • The large number of obtainable leads enables direct humanization and selection for CMC related quality criteria which results in a minimal modality risk for development.
  • In silico analysis of manufacturability as an intrinsic part of lead selection after humanization.
  • Transient recombinant expression selects for well producible molecules.
  • Selected fully humanized MABD antibodies have good drug-like characteristics.

Immunization

 

MAB Discovery delivers high quality, functional monoclonal antibodies via sophisticated, high-throughput selection of B cells generated by immunization. The immunogen can be a full-length recombinant or partially purified protein preparation, as well as whole cells, DNA or peptide conjugates. The MAB Discovery approach always delivers a vast number of high quality candidates with regard to potency and epitope coverage.

MAB Discovery employs a proprietary immunization schedule, enabling a focused and highly successful strategy for each and every individual antigen target. This schedule allows early prediction of project success.
The use of wild type rabbits for the immunization and functional B-cell cloning strategy of MAB Discovery suits not only classical target proteins and receptors, but also to a wide variety of more challenging immunogens, e.g. GPCRs, ion channels, carbohydrates, and small sized epitopes.

Key points immunization:

  • Many immunogens possible (Protein, cells, DNA,…)
  • Proprietary immunization schedule
  • Immunogen dependent immunization schedule
  • Different bleeds can be analyzed
  • Prediction of success at an early time point possible

B Cell Cloning

According to the targeted immunization and sampling schedule, peripheral blood lymphocytes are prepared. B-cells are cloned by fluorescence activated cell sorting (FACS) and deposited as single cells into proprietary growth medium. The cloning is fully automated and thousands of B cell clones can be sorted, which leads to a much higher hit rate compared to conventional hybridoma technology, other B-cell cloning methods or phage-library generation from immunized animals. This guarantees that most, if not all of the possible target epitopes can be accessed. During cultivation, these monoclonal B-cells secrete the monoclonal antibody into the supernatant. As natural diversity of light and heavy chain combination is not influenced by the MAB Discovery process, resulting monoclonal antibodies already exhibit high stability and affinity from the start. Therefore, costly, cumbersome and time-consuming affinity maturation steps are not required.

Key Points B Cell Cloning

  • Isolation of thousands of B cells ensures superior hit rate
  • Proprietary sampling, cloning and B-cell cultivation process ensures best in class and unique epitope coverage
  • Natural selection of light and heavy chain combination is retained; resulting in high specificity, stability and affinity
  • Automated, reliable and fast process

High-Throughput Screening

Cultivated B-cell clone supernatants contain sufficient quantities of monoclonal antibody to enable several screening assays to be run in parallel at an early stage. Whenever possible, cell-based functional assays are included. As monoclonal selection by binding alone is generally not sufficient to predict function as well as therapeutic efficiency, the inclusion of cell-based activity assays at this stage is key to the identification of therapeutic antibody candidates. B-cell clones with interesting activity are then picked and processed.
Where screening assays are not already in place, or not yet described in the literature MAB Discovery develops, wherever possible, customized assays and candidate selection strategies to ensure the most efficient and successful project delivery. If required, Fc mediated functions can also be tested.

Key points High-Throughput Screening:

  • Integration of functional assays at screening stage is the key to success
  • Ability to perform multiple assays from B cell clone supernatant greatly increases effectiveness of screening strategy
  • Screening for Fc mediated function possible due to 100% interaction with human Fc mediated receptor assays
  • Ability to set up assays from scratch or adapt established assays to our high-throughput platform
  • High throughput screening platforms ensures we discover the "rare event" so no blockbuster clones are ever left behind!
  • Integration of functional assays at screening stage is the key to success

Sequence Analysis and Humanization

 

B-cells and supernatants are separated after B cell cultivation. B-cell clones with interesting activity in the supernatant are processed, and the sequences of light and heavy chain variable regions are determined. This is followed by direct humanization of all antibodies or creation of a chimeric rabbit-human sequence. The codon-optimized sequence for mammalian expression as well as expression plasmids are synthesized accordingly.

Superior humanization protocols

To further leverage the MAB Discovery platform, we have partnered with a global leader in antibody humanization technologies, Fusion Antibodies, Belfast, UK, (www.fusionantibodies.com/).
This partnership enables clients to not only generate best in class, functional antibodies, but fully humanize them from the outset, saving months in project development.

Key points Sequencing and Humanization:

  • Antibody humanization is seamlessly built in to the platform shaving months of a project timeline
  • Sequencing of all the antibody hits light and heavy chain variable regions is possible ensuring complete security for downstream assessment
  • Sequence analysis including diversity assessment and screening for potential CMC liabilities helps inform lead candidate selection strategy
  • Different humanization workflows – classical and fast track- tailored to optimize the workflow.

Recombinant Expression

Recombinant expression of humanized or chimeric antibodies is part of the general discovery work-flow. During this process different formats of the constant domain can be selected depending on the intended application, including the selection of different natural or engineered Fc variants. The automated process is applied to up to several hundred recombinant humanized hits. HEK293 cells are transfected in an automated way; therefore, several hundred antibodies could be expressed at the same time. Following cultivation, the recombinant antibodies are purified from the cell supernatants. After purification, concentrations of the antibody containing eluates are determined and normalized to facilitate confirmation testing. Assay data of the primary screen are confirmed with the recombinantly produced antibodies. The confirmation yield from B-cell supernatant to recombinant hits is very high (80 to 90%). In addition, if required, larger amounts of selected candidate antibodies can be produced.

Key points recombinant expression:

  • Humanized or chimeric antibodies can be generated
  • Different isotypes and engineered Fc variants of immunoglobulins from different species available
  • Sufficient levels of protein readily available via scaled up expression ensuring there is no limit to downstream testing/screening
  • Identification of naturally high affinity antibodies means no affinity maturation is required saving significant time and cost
  • Recombinantly expressed monoclonals with an array of affinities and range of epitopes provides options for lead selection depending on predefined target product profiles

Project management

Professional project management by a team of highly experienced pharma and biotechnology experts is a cornerstone of the MAB Discovery collaboration offering. Indeed, MAB Discovery sees itself as an extension of a client’s internal drug discovery and R&D group; not as an independent contractor. Prior to project initiation, a project manager is assigned who coordinates all communication with the partner, including critical pre-project discussions around the establishment of the integrated functional screening assays.

Key points project management:

  • Highly experienced project managers, including large pharma industry project  experts
  • Customized project workflow and timing
  • Regular updates on deliverables and milestones
  • Reliable on-time communication

LIMS system

MAB Discovery employs a highly efficient, fully automated, high throughput platform from immunization to recombinantly expressed leads. All steps are embedded into a barcode guided data system, enabling retracing of all recombinantly produced antibodies back to its original B-cell clone. The high level of automation and full traceability allows the processing of hundreds of hits with high speed and efficiency. All data are stored in the MAB Discovery LIMS system. This proprietary data base ensures tracking and documentation, and is also integral part of the company's risk management system.

Key points LIMS system:

  • Cost efficient, automated platform for antibody generation enables levels of novel antibody discovery unsurpassed by manual methods
  • Full barcode tracking of the discovery and selection process ensuring full traceability and risk management
  • Data protection and documentation which comply with the most stringent pharma QA & RA requirements
  • LIMS controlled automation drives cost efficiency and speed

Working with us

MAB Discovery enables its collaboration partners to discover, isolate and characterize monoclonals of unprecedented quality in terms of potency, functionality and epitope coverage. Based on individual client consulting, customized study design, target selection, and immunization strategy, the robust MAB Discovery process recognizes all relevant aspects for fast and successful delivery of sets of fully functional monoclonal antibodies, even for very challenging antigens.

MAB Discovery provides a superior route from immunization to delivery of well-characterized candidate expressing cell lines. The technology has been successfully employed for big pharma customers, and allows for discovery of antagonists, agonists as well as development of novel anti-infective approaches and strategies.

MAB Discovery successfully shares its outstanding experience and leading technology position with its partners, and follows a flexible cooperation business model including a technology access fee, research funding, milestone payments, royalty components as well as flexible working packages based on FTE rate.

  • News & Events

EUROSTARS grants Project Funding for SPARKLE Consortium - MAB Discovery technology will be employed for selection and development of therapeutic antibodies against drug-resistant Klebsiella pneumoniae

Neuried, Germany – April 5, 2018:

MAB Discovery GmbH is part of the SPARKLE consortium of five partners which receives 36 months funding from the EUSTARS program (https://www.eurostars-eureka.eu/project/id/11302). The unique MAB Discovery technology platform for the generation of novel monoclonal antibody drugs will be applied to pave the way for innovative treatments of severe infections by multidrug resistant bacteria.

The consortium will develop and perform the preclinical validation of an innovative therapeutic strategy against antibiotic-resistant Klebsiella pneumoniae (ARKP) infections. Klebsiella pneumoniae (KP) is a common hospital-acquired pathogen for which, due to resistance, treatment options are very limited. The therapy is based on a therapeutic monoclonal antibody (mAb) that specifically targets ARKP. Upon completion of the project, the mAb product will be ready for further clinical development.

“We are dedicated to deliver a set of novel molecules for the treatment and cure of severe infections. Being a part of the SPARKLE consortium broadens the scope of applications and underscores again the high performance of our rabbit-based antibody discovery platform,” said Dr. Stephan Fischer, CEO of MAB Discovery.

MAB Discovery delivers high quality, functional monoclonal antibodies via sophisticated, high-throughput selection of B cells generated by immunization and delivers a vast number of high quality candidates with regard to potency and epitope coverage. The use of wild type rabbits for immunization and the functional B-cell cloning strategy of MAB Discovery suits not only classical target proteins and receptors, but also to a wide variety of more challenging immunogens.

About MAB Discovery

Founded in 2010 by Dr. Stephan Fischer, MAB Discovery utilizes a unique rabbit-based antibody discovery platform to develop high quality, functional monoclonal antibodies targeting traditional proteins and receptors as well as a wide variety of more challenging immunogens such as GPCRs and ion channels. The MAB Discovery team has extensive experience in developing antibody-based therapeutics having worked together at Roche Biologicals for several years. The company follows a flexible collaboration-based business model to meet the needs of its clients and ongoing partners. For additional information, please visit www.mabdiscovery.com.

Contact:

MAB Discovery:
Stephan Fischer
+49 89 990 178-0
stephan.fischer@mabdiscovery.com

For media inquiries:
MC Services AG
Dr. Claudia Gutjahr-Löser
+49 89 210 228-0
contact@mc-services.eu

„DiscoEpiMapp“ – Neuen Antikörpern auf der Spur

Stuttgart / Tübingen, 4. April 2018

Erstes Forschungs- und Entwicklungsprojekt im biohymed-Kooperationsnetzwerk

(Stuttgart/Tübingen) – Das Zentrale Innovationsprogramm Mittelstand (ZIM) des Bundesministeriums für Wirtschaft und Energie (BMWi) fördert den Aufbau des Kooperationsnetzwerkes „biohymed“ zur Entwicklung biohybrider Produkte und Verfahren. Gemeinsam mit Universitäten, Kliniken und wissenschaftlichen Instituten aus der Region sowie kleinen bzw. mittelständischen Unternehmen forciert die BioRegio STERN Management GmbH damit gezielt die Biologisierung der Medizintechnik. Im März trafen sich die drei Partner des ersten Forschungsprojektes, die gemeinsam die Technologieplattform „DiscoEpiMapp“ zur Charakterisierung von Antikörpern für medizinische Zwecke entwickeln.

Das biohymed-Netzwerk bietet den beteiligten Partnern ideale Rahmenbedingungen, um Förderung durch das BMWi für innovative Forschungs- und Entwicklungsprojekte zu erhalten. Dazu gehört die Technologieplattform „DiscoEpiMapp“, die von drei Projektpartnern aus dem biohymed-Netzwerk, dem Naturwissenschaftlichen und Medizinischen Institut (NMI) an der Universität Tübingen aus Reutlingen, der INTAVIS Bioanalytical Instruments AG aus Tübingen und der MAB Discovery GmbH aus Neuried bei München, entwickelt wird. DiscoEpiMapp soll 3D-Strukturen von Epitopen, also Molekülabschnitte eines Antigens, gegen den das Immunsystem Antikörper bildet, untersuchen.

Die therapeutische Anwendung von Antikörpern und Antikörper-Medikamenten gewinnt zunehmend an Bedeutung. Ein erster wichtiger Schritt der Entwicklung therapeutischer Antikörper ist die Identifizierung von Zielmolekülen, den sogenannten Targets. Diese können anschließend auf ihre Relevanz für bestimmte Krankheitsbilder hin überprüft werden. Oft handelt es sich bei den Zielmolekülen um große Moleküle, die sich als „Rezeptoren“ auf Oberflächen von Zellen, wie beispielsweise Krebszellen, befinden. Sie übertragen Signale von außen, etwa zur Zellteilung, ins Innere der Zelle. Therapeutische Antikörper erkennen hierbei einen kleinen Teil des Zielmoleküls: das Epitop. Als Therapeutikum können sie die Funktion des Zielmoleküls blockieren, indem sie an dieses Epitop binden. Antikörper binden mit ihrer Binderegion meist ganz spezifisch „ihr“ Epitop, vergleichbar mit dem „Schlüssel-Schloss-Prinzip“. Die genaue Beschreibung des Epitops ist dabei von großer Bedeutung, um den Wirkmechanismus des potenziellen Therapeutikums zu verstehen. Die frühzeitige möglichst genaue Erkennung der Binderegion eines therapeutischen Antikörperkandidaten an sein Targetmolekül ist somit ein besonders kritischer Meilenstein in der Entwicklung neuer Antikörpermedikamente. Bisherige Methoden, wie die aufwändige Röntgenkristallographie, sind aufgrund ihres geringen Durchsatzes nur begrenzt einsetzbar.

Genau hier setzt DiscoEpiMapp an: Das Projektteam entwickelt einen neuartigen 3D-Peptid-Array als molekularbiologisches Untersuchungssystem, das eine umfangreiche, schnelle und zuverlässige dreidimensionale Charakterisierung unterschiedlicher Antikörperkandidaten für medizinische Zwecke ermöglicht. Hierbei erarbeitet INTAVIS als Spezialist auf dem Gebiet der membrangebundenen Peptid-Synthese die 3D-Peptid-Array-Technologie. MAB Discovery testet den 3D-Array und entwickelt begleitend ein neuartiges Hochleistungs-Produktionssystem für Antikörper. Das NMI erweitert das Verfahren durch eine HDX-Massenspektrometrie-Analytik zur Epitop-Charakterisierung.

Dr. Verena Grimm, Projektleiterin der BioRegio STERN Management GmbH, blickt auf die erfolgreiche Bewilligung der Förderung für dieses erste Forschungs- und Entwicklungsprojekt im Rahmen von biohymed zurück: „Das biohymed-Netzwerk soll den Projektpartnern die Möglichkeit geben, innovative Technologien für die Medizin der Zukunft zu entwickeln. Durch die Verknüpfung der Kompetenzen von INTAVIS und MAB Discovery in Kooperation mit dem NMI als etabliertem Netzwerkpartner unterstützen wir die Entwicklung einer neuen Technologie zum Screening, zur Produktion und zur Qualitätskontrolle therapeutischer monoklonaler Antikörper für die forschen den Unternehmen der Pharmabranche.“

Über die BioRegio STERN Management GmbH:

Die BioRegio STERN Management GmbH ist Wirtschaftsentwickler für die Life-Sciences-Branche. Sie fördert im öffentlichen Auftrag Innovationen und Start-ups und trägt so zur Stärkung des Standorts bei. In den Regionen Stuttgart und Neckar-Alb mit den Städten Tübingen und Reutlingen ist sie die zentrale Anlaufstelle für Gründer und Unternehmer. Die BioRegion STERN zählt zu den großen und erfolgreichen BioRegionen in Deutschland. Alleinstellungsmerkmale sind die bundesweit einzigartige Mischung aus Biotechnologie- und Medizintechnikunternehmen sowie die regionalen Cluster der Automatisierungstechnik, des Maschinen- und Anlagenbaus.

BioRegio STERN: seit Frühling 2015 Träger des Silver Labels des ESCA.
Pressekontakt:

BioRegio STERN Management GmbH
Dr. Klaus Eichenberg
Friedrichstraße 10
70174 Stuttgart
0711-870354-0
eichenberg@bioregio-stern.de

www.twitter.com/BioRegioSTERN
www.facebook.com/BioRegioSTERN

Redaktion

Zeeb Kommunikation GmbH
Anja Pätzold
Hohenheimer Straße 58a
70184 Stuttgart
0711-6070719
info@zeeb.info

Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics

CAMBRIDGE, Mass. USA, and NEURIED, Germany, February 20, 2018:

CullinanOncology, LLC and MAB Discovery GmbH (MABD), announced today the initiation of a
collaboration to develop novel antibody therapeutics based on MABD’s unique discovery platform.

“We are excited to enter into this collaboration as the MABD development engine provides us with access to highly differentiated monoclonal antibodies” said Patrick Baeuerle, Cullinan’s Chief Scientific Officer, Biologics. “Our first program is a novel agonistic antibody that has the potential to be a pillar of future immuno-oncology and standard treatments. We look forward to working with Stephan Fischer and the MABD team to execute the development plan and progress the asset into the clinic.”

Under the terms of the agreement, MABD has the potential to receive cash payments upon the achievement of various milestones in addition to an upfront equity interest in Cullinan Wittelsbach, a subsidiary of Cullinan Oncology LLC formed to fund and shepherd the development of the asset.

Dr. Stephan Fischer, CEO of MAB Discovery, stated, “We are delighted to partner with Patrick and the Cullinan team, and look forward to understanding how the unique attributes of our rabbit-based platform translate into highly differentiated antibodies that have the potential to significantly advance patient outcomes.”

About Cullinan Oncology

Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, the company’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model. Cullinan is backed by the UBS Oncology Impact Fund (OIF) managed by MPM Capital, a worldwide leader in oncology investing, and F2 Ventures. For additional information, please visit www.cullinanoncology.com.

About MAB Discovery

Founded in 2010 by Dr. Stephan Fischer, MAB Discovery utilizes a unique rabbit-based antibody discovery platform to develop high quality, functional monoclonal antibodies targeting traditional proteins and receptors as well as a wide variety of more challenging immunogens such as GPCRs and ion channels. The MAB Discovery team has extensive experience in developing antibody-based therapeutics having worked together at Roche Biologicals for several years. The company follows a flexible collaboration-based business model to meet the needs of its clients and ongoing partners. For additional information, please visit www.mabdiscovery.com.

Collaboration project agreement between MAB Discovery GmbH and BioNTech AG

Neuried, Germany - November 6, 2017:
MAB Discovery GmbH today announced that it has entered into the second collaboration project agreement with BioNTech AG, Mainz. The unique MAB Discovery technology platform for the generation of novel antibody therapeutics will be applied for proprietary targets provided by BioNTech. Financial terms of the agreement were not disclosed.

“We are excited to be selected again as a partner for BioNTech. This underscores the high performance of our rabbit-based antibody discovery platform,” said Dr. Stephan Fischer, CEO of MAB Discovery.

Sean Marett, COO of BioNTech added, “Our collaboration with MAB Discovery in 2013 was highly productive and we are delighted to expand our relationship to generate unique antibodies against a set of therapeutically relevant targets.”

MAB Discovery delivers high quality, functional monoclonal antibodies via sophisticated, high-throughput selection of B cells generated by immunization, and delivers a vast number of high quality candidates with regard to potency and epitope coverage. The use of wild type rabbits for immunization and the functional B-cell cloning strategy of MAB Discovery suits not only classical target proteins and receptors, but also to a wide variety of more challenging immunogens, e.g. GPCRs, ion channels, carbohydrates, and small sized epitopes.

About MAB Discovery GmbH

MAB Discovery, based in Munich, was founded and established in 2010 by experienced pharma scientists with proven track record in drug development. MAB Discovery complies with the highest industrial standards of big pharma, but operates with the flexibility, speed and innovative spirit of young biotech’s. The company’s outstanding technology platform generally offers its collaboration partners access to a large variety of functional drug candidates to choose from, and a unique route to CMC-compliant humanized mAb’s in 10-12 months.

Contact:

MAB Discovery:
Stefan Müllner
+49 89 990 178-0
stefan.muellner@mabdiscovery.com

For media inquiries:
MC Services AG
Dr. Claudia Gutjahr-Löser
+49 89 210 228-0
contact@mc-services.eu

BioEurope


MAB Discovery will attend this years BioEurope in Berlin, November 6-8. We will be excited to meeting with you there to discuss your individual development projects.

  • Contact

How to find us

Map

MAB Discovery GmbH
Forstenrieder Straße 8 - 14
82061 Neuried
Germany

Email: info@mabdiscovery.com
Phone: +49 89 990 178-0
Fax: +49 89 990 178-199
Web: www.mabdiscovery.com

Arrival

By car

From A9 Nuernberg
Take the highway No. 68 to A 92 “Neufahrn” towards Stuttgart/Augsburg/München West and continue on highway A 99 direction Lindau/Stuttgart. Stay on A 99 towards Lindau take exit No. 4  onto A 96 towards Lindau. Keep right and take the first exit (No. 34) Germering/Krailling.  Turn left onto Germeringer Strasse. You are going through Planegg and continue on Münchener Strasse towards Neuried. MAB Discovery is in the center of Neuried just after a crossroad where you keep straight on. On the right side you will see the MAB Discovery sign and the entrance to the parking lot. MAB Discovery is in No. 10, ground floor.

From A8 Stuttgart and A96 Lindau
Take the highway exit No. 81 to A99, “München-West” towards Garmisch-P./Lindau and continue for about 7 km. Keep right and take the exit No. 4 to A 96 “München-Süd-West” towards Lindau. Take the first exit (No. 34), turn left onto Germeringer Strasse. You are passing Planegg and continue on Münchener Strasse. . MAB Discovery is in the center of Neuried just after a crossroad where you keep straight on. On the right side you will see the MAB Discovery sign and the entrance to the parking lot. MAB Discovery is in No. 10, ground floor.

From Munich Airport
Take main exit towards west/all directions, turn onto A 92 towards Munich for about 21 km. Then continue on A99 for about 17 km. Take exit No. 4 onto A 96 towards Lindau, keep right and take the first exit (No. 34) Germering/Krailling. Turn left onto Germeringer Strasse. You are going through Planegg and continue on Münchener Strasse towards Neuried. MAB Discovery is in the center of Neuried just after a crossroad where you keep straight on. On the right side you will see the MAB Discovery sign and the entrance to the parking lot. MAB Discovery is in No. 10, ground floor

By plane

Take the S-Bahn S1 or S8 from Munich Franz Joseph Strauss Airport to Marienplatz. Get off and change to the U-Bahn U3 to Fürstenried West. Get off at the terminal station and take the bus Nr 260, 267, or 936. Get off at Neuried Rathaus. Cross the street, turn left and go back 200m. On the right side you will see the MAB Discovery sign and the entrance to the parking lot. MAB Discovery is in No. 10, ground floor.

By public transport

From Munich main station, take the U1 to direction Manfallplatz, or U2 to direction Messestadt Ost change at Sendlinger Tor to U3 to Fürstenried West. Get off at the terminal station and take the bus Nr 260, 267, or 936. Get off at Neuried Rathaus. Cross the street, turn left and go back 200m. On the right side you will see the MAB Discovery sign and the entrance to the parking lot. MAB Discovery is in No. 10, ground floor.